FDA Advisory Committee Member discusses future of Johnson & Johnson vaccine
03:46
Share this -
copied
Federal agencies are expected to decide whether the Johnson & Johnson covid-19 vaccine can resume this week. Member of the FDA Vaccine Advisory Committee Dr. Paul Offit weighs in on the vaccine's fate and explains its advantages, but cautions it now has a "scarlet letter" on it. April 20, 2021
UP NEXT
Figure Skating gold medalist on Russian skating coach: ‘It was just alarming’
10:00
Schwartz on Valieva’s final skate: ‘One of the most tragic performances in ice skating history’
01:43
Local policy director on gun violence: ‘We will hold the gun industry accountable’
03:22
Chu on interest rates and high prices: ‘If rates go higher it will cost our country even more’
09:30
Kinsa CEO on Covid: ‘Cases are continuing to drop…but we aren’t out of the woods yet’
02:57
Brian Deese on rising inflation, impacts of Covid vaccine mandate protests in Canada